Previous 10 | Next 10 |
REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, ...
2024-02-26 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-08 18:42:29 ET Summary Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guara...
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® PR Newswire Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB ® , a Human Rabies Immune Globulin (HRIG) developed in partnershi...
2023-12-06 12:33:41 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), Kamada Ltd (NASDAQ: KMDA), Syros Pha...
2023-12-06 09:57:12 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), ZyVersa Therapeutics Inc (NASDAQ: ZVSA), Ka...
2023-12-06 07:51:10 ET More on Kamada Kamada: Solid Specialty Plasma Play Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript The AAT Caveat In Kamada's Upbeat Quarter Kamada beats Q3 top and bottom line estimates; reaffirms FY23 outlook Kamada Q3 202...
Largest Commercial Agreement in Kamada’s History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada O ver the First Four Years of the Eight Year Term Financial Terms Reflect KEDRAB® ...
2023-12-05 12:00:00 ET Summary In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top in...
2023-11-21 10:11:25 ET Summary Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company is expected to grow EBITDA significantly in the coming years through its existing business and potential acquisi...
News, Short Squeeze, Breakout and More Instantly...
Kamada Ltd. Company Name:
KMDA Stock Symbol:
NASDAQ Market:
2024-04-07 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-18 02:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-08 03:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...